header-logo header-logo

Patent

15 May 2015
Issue: 7652 / Categories: Case law , Law digest , In Court
printer mail-detail

Novartis AG and others v Focus pharmaceuticals Ltd and others; Novartis AG and others v Teva UK Ltd [2015] EWHC 1068 (Pat), [2015] All ER (D) 233 (Apr)

The Patents Court considered a claim for infringement of European Patent (UK) No 2 292 219 directed to the use of rivastigmine for use in the treatment of Alzheimer’s disease wherein the rivastigmine was administered by a transdermal therapeutic system. The court held that the patent was invalid on the ground of added matter and since the claimed invention lacked an inventive step over a previous patent.

If you are not a subscriber, subscribe now to read this content
If you are already a subscriber sign in
...or Register for two weeks' free access to subscriber content

MOVERS & SHAKERS

Hugh James—Phil Edwards

Hugh James—Phil Edwards

Serious injury teambolstered by high-profile partner hire

Freeths—Melanie Stancliffe

Freeths—Melanie Stancliffe

Firm strengthens employment team with partner hire

DAC Beachcroft—Tim Barr

DAC Beachcroft—Tim Barr

Lawyers’ liability practice strengthened with partner appointment in London

NEWS
Ceri Morgan, knowledge counsel at Herbert Smith Freehills Kramer LLP, analyses the Supreme Court’s landmark decision in Johnson v FirstRand Bank Ltd, which reshapes the law of fiduciary relationships and common law bribery
The boundaries of media access in family law are scrutinised by Nicholas Dobson in NLJ this week
Reflecting on personal experience, Professor Graham Zellick KC, Senior Master of the Bench and former Reader of the Middle Temple, questions the unchecked power of parliamentary privilege
Geoff Dover, managing director at Heirloom Fair Legal, sets out a blueprint for ethical litigation funding in the wake of high-profile law firm collapses
James Grice, head of innovation and AI at Lawfront, explores how artificial intelligence is transforming the legal sector
back-to-top-scroll